Related Experiment Video
Updated: Jul 2, 2026
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Targeted treatment and new agents in diffuse large B-cell lymphoma
John P Leonard1, Peter Martin, Jacqueline Barrientos
1Center for Lymphoma and Myeloma and Division of Hematology and Medical Oncology, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY 10021, USA. jpleonard@med.cornell.edu
Seminars in Hematology
|September 2, 2008
Summary
Rituximab with chemotherapy (R-CHOP) treats aggressive lymphoma, but new therapies are needed. Ongoing research explores novel agents and dose-dense regimens to improve outcomes for diffuse large B-cell lymphoma patients.
Area of Science:
- Hematology
- Oncology
- Clinical Pharmacology
Background:
- The standard chemoimmunotherapy regimen for aggressive non-Hodgkin's lymphoma (NHL), rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), is effective but not curative for all patients.
- Diffuse large B-cell lymphoma (DLBCL) remains a significant cause of mortality, necessitating advancements in therapeutic strategies.
- While the International Prognostic Index (IPI) is a validated prognostic tool, prospective data guiding its use for specific patient subsets are lacking.
Purpose of the Study:
- To review current therapeutic strategies for aggressive lymphoma, focusing on diffuse large B-cell lymphoma (DLBCL).
- To explore novel therapeutic agents and treatment approaches being evaluated for DLBCL.
- To discuss the challenges and future directions in optimizing DLBCL treatment.
Main Methods:
- Review of existing literature on R-CHOP therapy and its limitations in DLBCL.
- Examination of ongoing clinical trials and preclinical research for novel agents in DLBCL.
- Analysis of emerging therapeutic strategies, including dose-dense regimens and targeted therapies.
Main Results:
- R-CHOP therapy, while effective, leaves a substantial proportion of DLBCL patients with unmet therapeutic needs.
- Numerous novel agents, including lenalidomide, SGN-40, bevacizumab, Syk inhibitors, and others, are under investigation for DLBCL.
- Dose-dense R-CHOP and combination therapies are being explored to enhance treatment efficacy.
Conclusions:
- Despite advances, significant challenges remain in improving DLBCL treatment outcomes.
- Novel agents show promise but require rigorous evaluation to demonstrate added value.
- Effective integration and sequencing of new drugs into existing treatment paradigms are crucial for future therapeutic success in aggressive NHL.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...